AGP Limited Secures 1st Position at BCSR Awards 2023

AGP collaborates with Childlife Foundation on Children’s Day 2023

AGP Launched Peridots – A Thanda Solution to Acidity, Gas and Indigestion

AGP secures 2nd Position at BCR Awards 2022

AGP wins Top Exporter Award at 6th PPMA Summit

AGP sponsors KDSP Carnival 2023

AGP bags big win at GDEIB Awards 2023

AGP continues partnership with IBA

AGP continues collaboration with TCF

AGP joins hands with SKMF

AGP continues partnership with ACF

AGP conducts Allergy Awareness Session At Pak Turk Maarif

Gong-Ringing Ceremony of AGP at PSX

Home > Products > MyDekla

Product List

MyDekla

 

Generic:

Daclatasvir

Therapeutic Class:

Hepatitis C Antivirals

Composition:

MyDekla 60mg = Each film-coated tablet contains daclatasvir dihydrochloride equivalent to 60mg daclatasvir

Description:

MyDekla use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults

Indications

  • Hepatitis C genotype 1
  • Recurrent HCV infection post-liver transplant
  • Hepatitis C genotype 3

Dosage:

Genotype 1:

  • Without cirrhosis: MyDekla plus MyHep for 12 weeks
  • Compensated (Child-Pugh A) cirrhosis: MyDekla plus MyHep (sofosbuvir) for 12 weeks
  • Decompensated (Child-Pugh B or C) cirrhosis: MyDekla plus MyHep (sofosbuvir) plus ribavirin for 12 weeks
  • Posttransplant: MyDekla plus sofosbuvir MyHep (sofosbuvir) plus ribavirin for 12 weeks

Genotype 3:

  • Without cirrhosis: MyDekla plus MyHep (sofosbuvir) for 12 weeks
  • Compensated (Child-Pugh A) or decompensated (Child-Pugh B or C) cirrhosis: MyDekla plusMyHep (sofosbuvir) plus ribavirin for 12 weeks
  • Post transplant: MyDekla plus MyHep (sofosbuvir) plus ribavirin for 12 weeks

Presentation:

MyDekla 60 mg tab is available in pack of 28 tablets